Protein kinase Cα inhibitor protects against downregulation of claudin-1 during epithelial-mesenchymal transition of pancreatic cancer

Carcinogenesis. 2013 Jun;34(6):1232-43. doi: 10.1093/carcin/bgt057. Epub 2013 Feb 6.

Abstract

Protein kinase Cα (PKCα) is highly expressed in pancreatic cancer. However, the effects of PKCα on Snail and claudin-1, which play crucial roles in epithelial cell polarity during epithelial-mesenchymal transition (EMT), remain unclear. In this study, we investigated the mechanisms of regulation of Snail and claudin-1 via a PKCα signal pathway during EMT in pancreatic cancer cells and in normal human pancreatic duct epithelial cells (HPDEs). By immunostaining, overexpression of PKCα and downregulation of claudin-1 were observed in poorly differentiated human pancreatic cancer tissues and the pancreatic cancer cell line PANC-1. Treatment with the PKCα inhibitor Gö6976 transcriptionally decreased Snail and increased claudin-1 in PANC-1 cells. The PKCα inhibitor prevented upregulation of Snail and downregulation of claudin-1 during EMT induced by transforming growth factor-β1 (TGF-β1) treatment and under hypoxia in PANC-1 cells. The effects of the PKCα inhibitor were in part regulated via an extracellular signal-regulated kinase (ERK) signaling pathway. The PKCα inhibitor also prevented downregulation of the barrier function and fence function during EMT in well-differentiated pancreatic cancer cell line HPAC. In normal HPDEs, the PKCα inhibitor transcriptionally induced not only claudin-1 but also claudin-4, -7 and occludin without a change of Snail. Treatment with the PKCα inhibitor in normal HPDEs prevented downregulation of claudin-1 and occludin by TGF-β1 treatment and enhanced upregulation of claudin-1, -4, -7 and occludin under hypoxia. These findings suggest that PKCα regulates claudin-1 via Snail- and mitogen-activated protein kinase/ERK-dependent pathways during EMT in pancreatic cancer. Thus, PKCα inhibitors may be potential therapeutic agents against the malignancy of human pancreatic cancer cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Butadienes / pharmacology
  • Carbazoles / pharmacology
  • Cell Hypoxia
  • Cell Line, Tumor
  • Claudin-1 / biosynthesis*
  • Claudin-4 / biosynthesis
  • Claudins / biosynthesis
  • Down-Regulation / drug effects
  • Enzyme Inhibitors / pharmacology
  • Epithelial Cells / metabolism
  • Epithelial-Mesenchymal Transition*
  • Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors
  • Extracellular Signal-Regulated MAP Kinases / metabolism*
  • Humans
  • Nitriles / pharmacology
  • Occludin / biosynthesis
  • Pancreatic Ducts / metabolism
  • Pancreatic Neoplasms / metabolism
  • Protein Biosynthesis / drug effects
  • Protein Kinase C-alpha / antagonists & inhibitors
  • Protein Kinase C-alpha / biosynthesis
  • Protein Kinase C-alpha / metabolism*
  • RNA Interference
  • RNA, Small Interfering
  • Signal Transduction
  • Snail Family Transcription Factors
  • Transcription Factors / biosynthesis
  • Transcription Factors / genetics
  • Transcription Factors / metabolism*
  • Transforming Growth Factor beta1 / pharmacology
  • Up-Regulation / drug effects

Substances

  • Butadienes
  • Carbazoles
  • Claudin-1
  • Claudin-4
  • Claudins
  • Cldn7 protein, rat
  • Enzyme Inhibitors
  • Nitriles
  • Occludin
  • RNA, Small Interfering
  • Snai2 protein, rat
  • Snail Family Transcription Factors
  • Transcription Factors
  • Transforming Growth Factor beta1
  • U 0126
  • Go 6976
  • Protein Kinase C-alpha
  • Extracellular Signal-Regulated MAP Kinases